The PI3K/AKT Pathway Regulates Histone H3 Modification

PI3K/AKT 通路调节组蛋白 H3 修饰

• 批准号: 9243133
• 负责人: Jennifer Marie Spangle
• 金额: $ 13.61万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-08-01 至 2019-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9243133
• 关键词: Address; Affect; Affinity; American Cancer Society; Biology; Breast; Breast Cancer Model; Breast Cancer cell line; Cancer Biology; Cancerous; Cell Survival; Cell physiology; Chromatin; Clinical; Clinical Research; Communities; Competence; DNA Sequence Alteration; Data; Development; Disease; Drug Combinations; Drug resistance; EGFR inhibition; EZH2 gene; Epigenetic Process; Equilibrium; Ethics; Event; Excision; Foundations; Future; Gene Expression; Genes; Genetic; Genetic Transcription; Genomics; Goals; Growth; Hematologic Neoplasms; Histones; Human; In Vitro; Journals; Knowledge; Lysine; MLL gene; Malignant Neoplasms; Manuscripts; Mediating; Mentors; Metabolism; Methylation; Methyltransferase; Modification; Molecular; Mutate; Mutation; Nucleosomes; Oncogenic; Oncoproteins; Output; PI3K/AKT; PIK3CA gene; PTEN gene; Pathway interactions; Peer Review; Pharmacologic Substance; Phosphorylation; Proto-Oncogene Proteins c-akt; Publishing; Regimen; Regulation; Reporting; Research; Research Infrastructure; Research Personnel; Resources; Science; Signal Transduction; Solid; Solid Neoplasm; Testing; Therapeutic; Translations; Treatment Efficacy; Tumor Cell Line; Tumorigenicity; Viral; Work; Xenograft Model; cancer therapy; cancer type; career; cell growth; clinical application; histone demethylase; histone modification; in vivo; in vivo Model; inhibitor/antagonist; insight; malignant breast neoplasm; medical schools; novel; novel therapeutics; outcome forecast; permissiveness; pre-clinical; promoter; response; targeted treatment; tumor; tumorigenesis; tumorigenic

PROJECT SUMMARY PI3K/AKT pathway activation, most commonly occurring through PIK3CA mutation or PTEN inactivation, deregulates cell growth, metabolism, and cell survival and is a common and significant event in human cancer. Research now suggests that cancer is both a genetic and epigenetic disease, as changes to the chromatin landscape frequently occur. High levels of the H3K4me3 mark, indicative of transcriptional competence, is associated with a poor prognosis in some cancer types. The H3K4 histone demethylase KDM5A may mediate a drug resistant state in response to EGFR inhibition in PI3K-mutated cancers. Moreover, AKT previously was shown to decrease H3K27me3 through the phosphorylation of the H3K27 methyltransferase EZH2. I therefore investigated whether PI3K/AKT regulates transcriptional competence. My preliminary research and first, first- authored manuscript from my postdoctoral research demonstrate that AKT promotes cell growth by directly regulating KDM5A and increasing H3K4me3. These data provide the foundation for my future research goals described below. My immediate career goals are to ethically conduct high quality science and to publish my research in top tier, peer reviewed journals, such that I can become an independent investigator at the intersection of chromatin biology and oncogenic signaling. My immediate research-oriented goals are 100% embodied by the research plan I propose for the K99/R00. Within this proposal, I plan to first develop of a comprehensive understanding of how oncogenic PI3K/AKT promotes H3K4me3 (Aim 1). Because H3K4me3 has been reported as elevated in some solid cancers including breast cancer, I will generate and utilize preclinical xenograft models to define a strategy to reduce H3K4me3 in breast cancer (Aim 2). Finally, additional mechanisms by which oncogenic PI3K/AKT promotes transcriptional competence will be investigated, focusing on the functional consequence(s) of AKT-mediated H3T45 phosphorylation (Aim 3). Completion of these aims will provide additional understanding of the mechanistic underpinnings of PI3K/AKT signal transduction, and will inform future therapeutic regimens in PI3K-activated breast and other cancers. My doctoral research investigated the mechanisms by which a virally encoded oncoprotein activates AKT and mTORC1 to promote translation and oncogenic growth. Currently I am an American Cancer Society fellow in Dr. Tom Roberts' lab identifying mechanisms by which PI3K/AKT mediate transcriptional competence. These ongoing opportunities have extensively prepared me to address my overarching career goal to expose novel mechanisms by which PI3K deregulation drives cancer and exploit this understanding to develop durable and efficacious therapies for cancer. My mentor, the DFCI Cancer Biology department, and the larger DFCI and Harvard Medical School community are well-equipped and committed to providing me with the necessary resources and infrastructure to address the aims outlined in my research plan and work towards the accomplishment of my long-term career goals.

项目摘要 PI3K/AKT途径活化，最常见通过PIK3CA突变或PTEN失活发生， 细胞生长、代谢和细胞存活失调，是人类癌症中常见且重要的事件。 现在的研究表明，癌症既是一种遗传性疾病，也是一种表观遗传性疾病，因为染色质的变化， 景观经常出现。高水平的H3K4me3标记，指示转录能力， 与某些癌症类型的预后不良有关。H3K4组蛋白去甲基化酶KDM5A可能介导 PI3K突变癌症中对EGFR抑制反应的耐药状态。此外，AKT以前是 显示通过H3K27甲基转移酶EZH2的磷酸化降低H3K27me3。因此我 研究了PI3K/AKT是否调节转录能力。我的初步研究，首先，首先- 我的博士后研究手稿表明，AKT通过直接促进细胞生长， 调节KDM5A和增加H3K4me3。这些数据为我未来的研究目标提供了基础 如下所述 我近期的职业目标是道德地进行高质量的科学研究，并在顶级期刊上发表我的研究， 同行评审的期刊，这样我就可以成为一个独立的研究者在染色质的交叉点， 生物学和致癌信号。我的直接研究导向目标100%体现在研究中 我为K99/R00提出的计划。在这一建议中，我计划首先制定一项全面的 了解致癌的PI3K/AKT如何促进H3K4me3（目的1）。因为H3K4me3已经被 据报道，在包括乳腺癌在内的一些实体癌中， 临床前异种移植模型，以确定减少乳腺癌中H3K4me3的策略（目标2）。最后， 致癌的PI3K/AKT促进转录能力的其他机制将是 研究，集中于AKT介导的H3T45磷酸化的功能后果（Aim 3）。完成这些目标将提供更多的理解的机制基础， PI3K/AKT信号转导，并将为PI3K激活的乳腺癌和其他乳腺癌的未来治疗方案提供信息。 癌的 我的博士研究调查了病毒编码的癌蛋白激活AKT的机制， mTORC1促进翻译和致癌生长。目前，我是美国癌症协会的成员， 博士Tom Roberts的实验室确定了PI3K/AKT介导转录能力的机制。这些 持续的机会让我做好了充分的准备，以实现我的总体职业目标， PI3K失调驱动癌症的机制，并利用这种理解来发展 持久有效的癌症治疗方法。我的导师，DFCI癌症生物学系， 更大的DFCI和哈佛医学院社区装备精良，并致力于为我提供 必要的资源和基础设施，以实现我的研究计划中概述的目标，并努力实现 实现我的长期职业目标。